Cuba’s health ministry has begun a new, clinical, phase of the anti-COVID vaccine’s trials. The drug Subrana 2 will be tested by 900 volunteers aged 19-80 in the country, according to MehrNews.
The Cuban Finlay Institute and the Pasteur Institute of Iran are developing their joint vaccine against the novel pathogen. An anti-virus drug remains the most advanced one among Havana’s four selected vaccines to fight against the COVID-19. This week, Cuban-Iranian medicine is undergoing its human phase thanks to the joint effort by the two countries.
In fact, both nations are suffering from the US economic sanctions, so, developing their own anti-COVID vaccine is a must. In phase 2B clinical trial, 900 Cuban volunteers will be tested from today at two Havana medical centres for three weeks.
On January 10, the needed agreement was signed. According to the document, within the framework of joint cooperation in the field of clinical trials of the Subrana 2 vaccine, Cuba and Iran agreed follows. If phase 2 becomes successful, the next phase of clinical trials will be conducted in Tehran.
As of mid-January, all the initial stages of testing this corona vaccine on 140 Cuban volunteers have been completed successfully without any side effects.
